Core Viewpoint - The "Development Plan for the Open Innovation of the Biopharmaceutical Industry Chain in China (Jiangsu) Free Trade Zone" aims to enhance the biopharmaceutical industry's R&D innovation capabilities and improve service levels by implementing 18 key tasks across seven areas, with a target for significant growth by 2030 [1][2]. Group 1: Key Objectives and Tasks - The plan targets rapid growth in the biopharmaceutical industry scale in Jiangsu by 2030, with a focus on optimizing the innovation ecosystem and modernizing the industry chain [1]. - It aims to establish distinctive industrial clusters in key areas such as macromolecular biopharmaceuticals, cell and gene therapy, and innovative medical devices [1]. - The plan emphasizes the importance of the free trade zone as a comprehensive experimental platform for reform and innovation in the biopharmaceutical sector [1]. Group 2: R&D Innovation - The plan includes measures to enhance R&D innovation, focusing on advanced treatment methods like immunotherapy, stem cell therapy, and in vitro diagnostic reagents [2]. - It proposes the application of big data and artificial intelligence in drug target screening, molecular design, and medical device manufacturing [2]. - Support for clinical research in immunotherapy, stem cell therapy, and gene therapy is encouraged, along with participation in the formulation of national and industry standards [2]. Group 3: Production and Distribution - The plan suggests exploring pilot projects for segmented production of chemical raw materials and biological products [2]. - It supports regulatory reforms for the import and export of experimental animals and expands the pilot scope of the "white list" system for R&D materials [2]. Group 4: Financial Support and Data Management - The plan outlines five key tasks related to enhancing financial support for the biopharmaceutical industry, including facilitating financing for innovative companies through various stock exchanges and bond issuance [4]. - It encourages the establishment of investment sub-funds and supports the issuance of real estate investment trusts (REITs) for qualifying biopharmaceutical projects [4]. - The plan addresses cross-border data flow concerns by proposing a negative list for data export in the biopharmaceutical sector and establishing a public service platform for data security [4].

Core Viewpoint - The article discusses the recently approved "Development Plan for Open Innovation of the Biopharmaceutical Industry Chain in China (Jiangsu) Free Trade Pilot Zone," which aims to enhance the biopharmaceutical industry's innovation capabilities and modernize its supply chain by 2030 [2]. Group 1: Key Tasks and Goals - The plan outlines 7 key areas and 18 specific tasks to promote integrated innovation across the entire biopharmaceutical industry chain [2]. - By 2030, the goal is to achieve rapid growth in the biopharmaceutical industry scale, optimize the innovation ecosystem, significantly enhance the modernization level of the industry chain, and improve the level of openness [2]. Group 2: R&D and Innovation - The plan emphasizes the importance of R&D innovation, focusing on advanced treatment methods such as immune cells, stem cells, and gene therapy, as well as innovative medical devices [3]. - Specific measures include strengthening the application of big data and artificial intelligence in drug design and medical device manufacturing, and supporting clinical research in relevant fields [3]. Group 3: Production and Distribution - The plan proposes pilot projects for segmented production of chemical raw materials and biological products, and reforms in the supervision of imported experimental animals [4]. - It aims to enhance the convenience of customs clearance for medical and research materials, leveraging Jiangsu's strong innovation capabilities and complete industry chain [4]. Group 4: Financial Support and Investment - The plan includes significant financial support measures, allowing qualified biopharmaceutical companies to list on various stock exchanges and issue bonds for financing [5]. - It encourages the establishment of investment funds focused on the biopharmaceutical industry and the issuance of real estate investment trusts (REITs) for eligible projects [5]. Group 5: Data Management - The plan highlights the importance of data management in the biopharmaceutical sector, proposing the development of a negative list for data export in this field [6]. - This initiative aims to facilitate efficient data export processes for companies, which is crucial for the overall development of the biopharmaceutical industry [6].

Core Viewpoint - The article discusses the "Development Plan for Open Innovation of the Biopharmaceutical Industry Chain in the China (Jiangsu) Pilot Free Trade Zone," which aims to enhance the biopharmaceutical industry's innovation capabilities and modernize its supply chain by 2030 [2]. Group 1: Key Objectives and Tasks - The plan includes 7 key areas and 18 specific tasks focused on integrated innovation across the entire biopharmaceutical industry chain [2]. - By 2030, the goal is to achieve rapid growth in the biopharmaceutical industry scale, optimize the innovation ecosystem, and significantly enhance the modernization level of the industry chain [2]. Group 2: R&D and Innovation - The plan emphasizes the importance of R&D innovation, particularly in advanced treatment methods such as immunotherapy, stem cell therapy, and gene therapy [4]. - It proposes measures to strengthen the application of big data and artificial intelligence in drug design and medical device manufacturing [4]. Group 3: Production and Distribution - The plan suggests exploring pilot projects for segmented production of chemical raw materials and biological products, as well as reforming the regulatory model for imported experimental animals [5]. - It aims to improve the convenience of customs clearance for medical and research materials, leveraging Jiangsu's strengths in biopharmaceutical innovation [5]. Group 4: Financial Support and Investment - The plan highlights the need for enhanced financial support, allowing qualified biopharmaceutical companies to list on various stock exchanges and issue bonds for financing [7]. - It encourages the establishment of investment funds specifically for the biopharmaceutical industry and supports the issuance of real estate investment trusts (REITs) for eligible projects [7]. Group 5: Data Management and Cross-Border Flow - The plan addresses concerns regarding cross-border data flow in the biopharmaceutical sector, proposing the development of a negative list for data export in this field [8]. - The establishment of a public service platform for data export safety is also part of the initiative, which aims to facilitate efficient data management for enterprises [8].

Core Viewpoint - The Jiangsu Free Trade Zone aims to enhance the biopharmaceutical industry through an open innovation development plan, targeting significant growth and modernization by 2030 [4][5]. Group 1: Overall Requirements - The plan is guided by Xi Jinping's thoughts and aims to create a globally influential biopharmaceutical hub in Jiangsu, focusing on high-quality development and safety [4][5]. Group 2: Enhancing R&D Innovation Capabilities - The initiative supports major national science and technology projects in biopharmaceuticals, emphasizing breakthroughs in innovative drugs and high-end medical devices [5][6]. - It promotes the application of big data and artificial intelligence in drug design and medical device manufacturing [5][6]. - The establishment of a national biopharmaceutical technology innovation center in Suzhou is encouraged to facilitate technology transfer and application [6][7]. Group 3: Improving Product Approval Services - The plan aims to optimize drug review services and enhance the approval process for innovative drugs and medical devices [8][9]. - It includes strengthening inspection and testing capabilities for biological products, particularly vaccines [8][9]. Group 4: Building a Biopharmaceutical Production and Distribution System - The initiative focuses on developing advanced manufacturing clusters for biopharmaceuticals and high-end medical devices [9][10]. - It aims to enhance customs facilitation for medical devices entering special regulatory zones [9][10]. Group 5: Enhancing Procurement and Usage Policies - The plan encourages the inclusion of eligible innovative drugs in the national medical insurance catalog and aims to streamline the approval process [10][11]. - It explores the introduction of AI-assisted diagnostic technologies in medical services [10][11]. Group 6: Increasing Support for Key Elements - The initiative proposes a market-oriented evaluation mechanism for talent in the biopharmaceutical sector [11][12]. - It supports financial backing for innovative biopharmaceutical companies through various funding avenues [11][12]. Group 7: Ensuring Safety and Risk Management - The plan emphasizes the importance of safety management in biopharmaceutical production and the need for robust risk assessment mechanisms [13][14]. - It aims to align regulatory capabilities with international standards to enhance drug and medical device oversight [13][14].

Core Viewpoint - The Ministry of Commerce and the Jiangsu Provincial Government have issued a development plan for the biopharmaceutical industry chain in the China (Jiangsu) Free Trade Zone, focusing on innovation and technological advancement in biomedicine and medical devices [1] Group 1: Innovation and Technology - The plan emphasizes the need for technological innovation in biomedicine and medical devices [1] - It supports the implementation of major national scientific projects in the biopharmaceutical sector [1] - The initiative aims to break through key core technologies in innovative drugs and high-end medical devices [1] Group 2: Data and AI Applications - There is a strong focus on the application of big data and artificial intelligence in drug target screening, drug molecular design, and the design and manufacturing of medical devices [1] - The plan encourages enterprises to participate in the formulation of national and industry standards for cell and gene therapy products, AI medical devices, biomedical materials, and in vitro diagnostic reagents [1]

Core Viewpoint - The Ministry of Commerce and the Jiangsu Provincial Government have issued a development plan for the open innovation of the entire biopharmaceutical industry chain in the China (Jiangsu) Pilot Free Trade Zone, focusing on technological innovation in biomedicine and medical devices [1] Group 1: Technological Innovation - The plan emphasizes the need to support the implementation of major national scientific and technological projects in the biopharmaceutical field [1] - It aims to leverage new research organizations to achieve breakthroughs in innovative drugs and key core technologies for high-end medical devices [1] - The application of big data and artificial intelligence in drug target screening, drug molecular design, and medical device design and manufacturing is highlighted [1] Group 2: Standardization and Industry Participation - Companies are encouraged to participate in the formulation of national and industry standards for cell and gene therapy products, artificial intelligence medical devices, biomedical materials, and in vitro diagnostic reagents [1]

Core Viewpoint - The "China (Jiangsu) Free Trade Pilot Zone Biopharmaceutical Industry Chain Open Innovation Development Plan" aims to enhance the biopharmaceutical industry in Jiangsu, focusing on innovation, international competitiveness, and high-quality development by 2030 [5][6]. Group 1: Overall Requirements - The plan is guided by Xi Jinping's thoughts and aims to create a world-class biopharmaceutical industry cluster in Jiangsu, with significant growth in industry scale and modernization by 2030 [6]. - Key areas of focus include breakthroughs in major technologies, especially in large molecule biopharmaceuticals, cell and gene therapy, and innovative medical devices [6]. Group 2: Enhancing R&D Innovation Capability - Support for national major projects in biopharmaceuticals and medical devices, emphasizing the use of big data and AI in drug design and medical device manufacturing [7]. - Establishment of a national biopharmaceutical technology innovation center in Suzhou and promotion of health data management standards [7][8]. - Encouragement of international collaborative research and optimization of clinical trial approval processes for foreign investments [8]. Group 3: Improving Product Approval Services - Optimization of drug review services to prioritize innovative drugs and medical devices, including AI medical service software [9]. - Enhancement of inspection and testing capabilities for biopharmaceuticals, particularly vaccines [9]. Group 4: Building Production and Distribution Systems - Development of advanced manufacturing clusters for biopharmaceuticals and high-end medical devices, including contract research and production services [10]. - Improvement of customs facilitation for medical devices not sold in China [10]. Group 5: Procurement and Usage Policies - Promotion of innovative drugs into the national medical insurance catalog and optimization of the listing process [11]. - Expansion of medical service offerings to include AI-assisted diagnostic technologies [11]. Group 6: Strengthening Support and Guarantee Measures - Implementation of talent evaluation policies tailored to the biopharmaceutical industry and facilitation of work permits for foreign medical professionals [12]. - Financial support for innovative biopharmaceutical companies through various funding mechanisms, including public offerings and investment funds [12][13]. Group 7: Ensuring Safety and Risk Management - Strengthening safety production supervision in the biopharmaceutical sector and enhancing risk management for high-risk products [14]. - Building regulatory capabilities in line with international standards for drug and medical device oversight [14]. Group 8: Collaborative Implementation - Jiangsu Provincial Government is responsible for implementing the plan, with support from various national departments to ensure effective execution [15].